Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Malignant Pleural Mesothelioma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Mesothelioma (88
)
Mesothelioma (88
)
›
Associations
(33)
News
Trials
Search handles
@AndresFCardonaZ
@DrJNaidoo
@Dr_Ivanoncologo
@FordePatrick
@VivekSubbiah
@giusvisc
Search handles
@AndresFCardonaZ
@DrJNaidoo
@Dr_Ivanoncologo
@FordePatrick
@VivekSubbiah
@giusvisc
Filter by
Latest
8ms
Meet the Author: Dr. Desai (@ADesaiMD), a Heme/Onc Fellow and #ECR from @MayoCancerCare @MayoHemOnc, is 1st author of “Dynamics and survival association of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy,” recently published in #JITC! 1/8 (@jitcancer)
8 months ago
Clinical
9ms
Epidemiology of Pleural Mesothelioma @JTOonline: - 2766 pts from @etop_ibcsg #mesoscape & @thoracic - females, epithelioid subtype, earlier stage assoc w ⬆️OS - multimodality tx w surgery assoc w ⬆️OS @OncoAlert #LCSM https://t.co/m6aEWXM8bs (@DrJNaidoo)
9 months ago
Clinical • Surgery
9ms
Great start of the iMig conference! All here !!! Clinicians, patient advocates, scientists —> to learn ☝🏻, create collaborative efforts 🤝 and get inspired 👁️ by research in #mesothelioma @PleuralMeso @CancerAlliance @Mesouk and many friends @DrSanjayPopat @fedgrosso .. (@MdCurioni)
9 months ago
Clinical
10ms
New #JITC article: Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy https://t.co/1aQqBvngFc @ADesaiMD @AMansfieldMD (@jitcancer)
10 months ago
Clinical
10ms
A few @eaonc poster presentations in #lungcancer (current trials) Sun 6/4 1st line Durvalumab w/chemo in advanced pleural #mesothelioma @FordePatrick ECOG-ACRIN LUNG-MAP substudy: phase II - sotorasib in prev treated pts with #KRAS G12C @SukiPaddaMD #LCSM @KRASKickers #ASCO23 (@jillfeldman4)
10 months ago
Clinical • P2 data • Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12C • KRAS G12
|
Imfinzi (durvalumab) • Lumakras (sotorasib)
10ms
The author’s aim was “to combine [malignant pleural mesothelioma] MPM patient samples, MPM patient derived xenograft (PDX) models and DBP to identify drug combinations that prime MPM cells and validate DBP as an approach to identify efficacious drug combinations.” #mesothelioma (@FL_Meso_Lawyer)
10 months ago
Clinical
12ms
when tumor T-cell infiltration is not enough targetable adaptive immunosuppressive pathways (IL6, CXCL8, VEGF, CTLA-4,..) involved in primary resistance to ICIs in pleural mesothelioma https://t.co/mRA6OEW50z (@giusvisc)
12 months ago
IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
over1year
Interestingly, the biomarker #BAP1 can determine the best treatment options for patients with #pleural #mesothelioma and may represent a step toward more personalized #treatment for this aggressive disease. @lungcancerhita @Lungsolutions @oncoOuLungCA https://t.co/kw6nSC2KF9 (@Dr_Ivanoncologo)
over 1 year ago
Clinical
|
BAP1 (BRCA1 Associated Protein 1)
almost2years
Ph II trial Tazemetostat (EZH2i) in pre-txd BAP1-inactivated malignant pleural mesothelioma: - 74pts - 54% DCR, mOS 36 wks - g3+TRAEs: hyperglycemia; hypoNa (7%) Moving towards a targeted approach in MPM Congrats #ASCOLDP21 @MGZauderer @OncoAlert #LCSM https://t.co/ESkXhASbbs (@DrJNaidoo)
almost 2 years ago
BAP1 (BRCA1 Associated Protein 1)
|
Tazverik (tazemetostat)
almost2years
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study https://t.co/Pvpd2b2uuu (@VivekSubbiah)
almost 2 years ago
Clinical
|
BAP1 (BRCA1 Associated Protein 1)
|
Tazverik (tazemetostat)
2years
The predictive and prognostic nature of PD-L1 in malignant pleural mesothelioma: a systematic literature review https://t.co/zpyBMdezON (@FordePatrick)
2 years ago
Review
|
PD-L1 (Programmed death ligand 1)
over2years
Proud to be part of knowledge from INCaN Thoracic Oncology Unit - RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin (@AndresFCardonaZ)
over 2 years ago
Clinical
|
ERCC1 (Excision repair cross-complementation group 1) • RRM1 (Ribonucleotide Reductase Catalytic Subunit M1)
|
cisplatin • gemcitabine
almost3years
https://t.co/1eyhaIWNKm So, after dr. Raphael Bueno @DanaFarber scrapped Pembrolizumab + Defactinib In Pleural Mesothelioma clinical study, it appears new plan is to combine ICIs with #FAKi Defactinib? #Nivo #IPI #Immune #checkpoint #inhibitors (ICIs) #HIPPO #YAP #TAZ #MPM #PDL1 (@CrozrX)
almost 3 years ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • defactinib (VS-6063)
over3years
⬇️ .@AMansfieldMD, of the @MayoCancerCare, discussed the clinical trial currently available across the U.S. and Canada with keytruda (pembrolizumab) used with or without anetumab ravtansine in patients with pleural #mesothelioma with a mesothelin expression. (@curemeso)
over 3 years ago
Clinical • PD(L)-1 Biomarker
|
MSLN (Mesothelin)
|
MSLN expression
|
Keytruda (pembrolizumab) • anetumab ravtansine (BAY 94-9343)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login